市場調查報告書
商品編碼
1402537
北美眼藥水市場預測至 2030 年 - 區域分析 - 按類型(抗生素、人工淚液、激素等)、應用和購買模式(非處方藥和處方藥)North America Eye Drops Market Forecast to 2030 - Regional Analysis - by Type (Antibiotics, Artificial Tears, Hormones, and Others), Application, and Purchase Mode (OTC and Prescription) |
北美眼藥水市場預計將從2022年的803,088萬美元成長到2030年的12,289.12百萬美元。預計2022年至2030年CAGR為5.5%。
眼科疾病盛行率上升推動北美眼藥水市場
導致視力損害的糖尿病視網膜病變、青光眼和乾眼症等眼科疾病的發生率在人群中不斷上升,特別是在已開發國家。乾眼症是由多種因素引起的,這些因素會導致不適、刺激和視力障礙。根據 2020 年 4 月在美國進行的一項「全國健康與健康調查」研究,約有 1,640 萬人被診斷出患有乾眼症。資料還表明,18-34歲族群的盛行率激增2.7%。據 Novaliq GmbH 稱,目前約有 1700 萬美國人患有乾眼症。
糖尿病視網膜病變代表微血管終末器官損傷。它從非增殖性糖尿病視網膜病變階段進展為增殖性糖尿病視網膜病變。隨著疾病的進展,相關的糖尿病黃斑水腫也可能變得明顯。根據美國眼科學會發表的一篇文章,預計到 2030 年,全球將有 1.91 億人患有糖尿病視網膜病變。據 Medscape 稱,美國約有 70 萬人患有增殖性糖尿病視網膜病變,每年新增病例約 65,000 例。
根據世界衛生組織 (WHO) 2022 年發表的一篇文章,全球約有 22 億人患有近視或遠視視力障礙。視力障礙的主要原因是白內障(約 9,400 萬例)和未矯正的屈光不正(約 8,840 萬例)。醫生通常會開眼藥水來治療和預防眼科疾病。因此,眼科疾病的日益普及正在推動北美眼藥水市場的成長。
北美眼藥水市場概況
北美眼藥水市場分為美國、加拿大和墨西哥。該地區的市場成長歸因於人們對乾眼症的認知不斷提高、人口老化的增加以及眼部治療程序的技術進步以及眼部疾病發病率的上升。乾眼症在美國是一種常見但診斷不足的疾病。不斷成長的老年人口進一步引發了乾眼症的流行。根據美國疾病管制與預防中心 (CDC) 的數據,黃斑部病變、白內障、糖尿病視網膜病變和青光眼等與年齡相關的眼部疾病是美國失明和低視力的主要原因。該國報告的其他常見眼部疾病包括弱視和斜視。隨著人口老化和年輕人接受屈光手術頻率的增加,預計到 2030 年,乾燥症將影響美國多達 279 萬名男性。
美國是北美眼藥水市場最大且成長最快的國家。該國的市場歸因於人們乾眼症發病率的增加。美國有多家公司提供不同的眼藥水和鏡片來治療乾眼症。此外,醫療保健支出的增加有利於美國北美眼藥水市場的成長。
北美眼藥水市場收入及 2030 年預測(百萬美元)
北美眼藥水市場細分
北美眼藥水市場按類型、應用、購買模式和國家細分。
根據類型,北美眼藥水市場分為抗生素、人工淚液、荷爾蒙等。 2022年,抗生素細分市場在北美眼藥水市場中佔據最大佔有率。
根據應用,北美眼藥水市場分為眼部疾病、眼部護理等。 2022年,眼疾細分市場在北美眼藥水市場中佔據最大佔有率。眼疾細分市場進一步細分為乾眼症、青光眼、白內障等。
根據購買模式,北美眼藥水市場分為非處方藥和處方藥。 2022 年,處方藥細分市場在北美眼藥水市場中佔據更大佔有率。
根據國家/地區,北美眼藥水市場分為美國、加拿大和墨西哥。 2022年,美國主導北美眼藥水市場。
艾伯維公司、Akorn Operating Company LLC、愛爾康公司、博士倫公司、輝瑞公司、Prestige Consumer Healthcare Inc.、樂敦製藥有限公司和 Similasan Corp 是北美眼藥水市場上的一些領先公司。
The North America eye drops market is expected to grow from US$ 8,030.88 million in 2022 to US$ 12,289.12 million by 2030. It is estimated to grow at a CAGR of 5.5% from 2022 to 2030.
Rising Prevalence of Ophthalmic Diseases Fuels North America Eye Drops Market
The incidence of ophthalmic diseases such as diabetic retinopathy, glaucoma, and dry eye leading to vision impairment is rising among the population, especially in developed countries. A dry eye is caused by multiple factors that result in discomfort, irritation, and visual disturbance. According to a study, "National Health and Wellness Survey," conducted in the US in April 2020, ~16.4 million people were diagnosed with dry eye. The data also stated that the prevalence had surged by 2.7% among people aged 18-34 years. According to Novaliq GmbH, ~17 million Americans currently suffer from dry eye disease.
Diabetic retinopathy represents microvascular end-organ damage. It progresses from non-proliferative diabetic retinopathy stages to proliferative diabetic retinopathy. As the disease progresses, associated diabetic macular edema may also become apparent. According to an article published by the American Academy of Ophthalmology, it is estimated that by 2030 an estimated 191 million people globally will suffer from diabetic retinopathy. According to Medscape, ~700,000 people in the US suffer from proliferative diabetic retinopathy, with ~65,000 new cases recorded annually.
According to an article published by the World Health Organization (WHO) in 2022, ~2.2 billion people worldwide suffer from near or distant vision impairment. The leading causes of vision impairment are cataracts (~94 million cases) and uncorrected refractive errors (~88.4 million cases). Doctors generally prescribe eye drops for the treatment and prevention of ophthalmic diseases. Hence, the increasing prevalence of ophthalmic diseases is fueling the growth of the North America eye drops market .
North America Eye Drops Market Overview
The North America eye drops market has been segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the rising awareness of dry eye conditions, an increase in the aging population, and technological advancements in eye treatment procedures with the rising incidence of eye disorders. Dry eye disease is a common but underdiagnosed condition in the US. The growing geriatric population further triggers the prevalence of dry eye disease. According to the Centers for Disease Control and Prevention (CDC), age-related eye diseases such as macular degeneration, cataract, diabetic retinopathy, and glaucoma are the leading causes of blindness and low vision in the US. Other common eye disorders reported in the country include amblyopia and strabismus. With aging populations and the increased frequency of younger adults receiving refractive surgeries, dry eye is expected to affect as many as 2.79 million men in the US by 2030.
The US is the largest and fastest-growing country in the North America eye drops market. The market in this country is ascribed to the increasing incidence of dry eye disease among people. Various companies offering different eye drops and lenses to treat dry eye condition have presence in the US. Also, the rising healthcare expenditure favors the growth of the North America eye drops market in the US.
North America Eye Drops Market Revenue and Forecast to 2030 (US$ Million)
North America Eye Drops Market Segmentation
The North America eye drops market is segmented into type, application, purchase mode, and country.
Based on type, the North America eye drops market is segmented into antibiotics, artificial tears, hormones, and others. The antibiotics segment held the largest share of the North America eye drops market in 2022.
Based on application, the North America eye drops market is segmented into eye diseases, eye care, and others. The eye diseases segment held the largest share of the North America eye drops market in 2022. The eye diseases segment is further segmented into dry eye, glaucoma, cataract, and others.
Based on purchase mode, the North America eye drops market is segmented into OTC and prescription. The prescription segment held a larger share of the North America eye drops market in 2022.
Based on country, the North America eye drops market is segmented into the US, Canada, and Mexico. The US dominated the North America eye drops market in 2022.
AbbVie Inc, Akorn Operating Company LLC, Alcon AG, Bausch & Lomb Inc, Pfizer Inc, Prestige Consumer Healthcare Inc., Rohto Pharmaceutical Co Ltd, and Similasan Corp are some of the leading companies operating in the North America eye drops market.